Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Non-Small-Cell Lung 20Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Lung Neoplasms 14Mouth Neoplasms 10Laryngeal Neoplasms 10Carcinoma 10Urinary Bladder Neoplasms 8Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 6Mesothelioma, Malignant 6Medulloblastoma 6Gallbladder Neoplasms 6Neuroblastoma 5Ganglioneuroblastoma 5Fallopian Tube Neoplasms 5Lymphoid Interstitial Pneumonia 4Vulvar Neoplasms 3Urethral Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Carcinoma, Transitional Cell 3Brenner Tumor 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1berzosertib 1aldesleukin 1Platinum 1Immunoglobulin G 1Gemcitabine 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Bladder Urothelial Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡